SCHEMBL4472453

SCHEMBL4472453

Cc1[nH]c(C)c(-c2ccc(Oc3ccc(OC(F)(F)F)cc3)cc2)c(=O)c1Cl

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 1/20 0.58
KIF11 P52732 1/20 0.39
PTGS2 P35354 2/20 0.38
NPBWR1 P48145 1/20 0.37
MCHR1 Q99705 1/20 0.37
NOTUM Q6P988 1/20 0.37
POLB P06746 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
PSD A5PKW4 1/20 0.36
KCNH2 Q12809 2/20 0.35
SCN10A Q9Y5Y9 2/20 0.35
SCN1A P35498 1/20 0.35
SCN5A Q14524 1/20 0.35
SCN9A Q15858 1/20 0.35
SCN2A Q99250 1/20 0.35
SCN8A Q9UQD0 1/20 0.35
MMP2 P08253 1/20 0.35
MMP9 P14780 1/20 0.35
MMP8 P22894 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9266167 0.91 SLC2A1 (0.51) SLC2A1PTGS2POLBSCN9A
SCHEMBL9268964 0.87 SLC2A1 (0.58) SLC2A1KIF11PTGS2NPBWR1MCHR1
SCHEMBL3561397 0.87 SLC2A1 (0.49) SLC2A1KIF11PTGS2NPBWR1MCHR1
SCHEMBL3559270 0.87 SLC2A1 (0.43) SLC2A1KIF11PTGS2NPBWR1MCHR1
SCHEMBL4481797 0.86 SLC2A1 (0.44) SLC2A1PTGS2NPBWR1MCHR1NOTUM
SCHEMBL3110262 0.86 SLC2A1 (0.43) SLC2A1KIF11PTGS2KCNH2SCN10A
SCHEMBL3556733 0.86 SLC2A1 (0.48) SLC2A1KIF11PTGS2KCNH2SCN10A
SCHEMBL9270359 0.85 SLC2A1 (0.78) SLC2A1PTGS2POLB
SCHEMBL3713576 0.85 SLC2A1 (0.42) SLC2A1
SCHEMBL3560079 0.84 SLC2A1 (0.42) SLC2A1KIF11PTGS2NPBWR1MCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1991013873-A1 HETEROCYCLIC COMPOUNDS THE WELLCOME FOUNDATION LIMITED (GB) 1991-09-19 WO claimed
CN-110545815-B Medical application of cytochrome bc1 complex inhibitor 北京蔚蓝之源医药科技有限公司 2024-07-05 CN disclosed
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-5403934-A Heterocyclic compounds BURROUGHS WELLCOME CO. (US) 1995-04-04 US disclosed
WO-1991013873-A1 HETEROCYCLIC COMPOUNDS THE WELLCOME FOUNDATION LIMITED (GB) 1991-09-19 WO disclosed
EP-0447164-A1 Heterocyclic compounds THE WELLCOME FOUNDATION LIMITED (GB) 1991-09-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287461-A1 Pyridinone Derivatives Against Malaria G6PD, PNPO, PLPBP SLC2A1 2278/4885KIF11 2269/4885PTGS2 1111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.